Figure 1.3 Costs associated with the prescribing of antipsychotic medications in the United States, 2002 through 2008, categorised by off-label status and level of supporting evidence. Reprinted with permission from Ref. [45]. © Nature Publishing Group/Macmillan.

Figure 4.5 Neurontin (gabapentin) prescriptions, by indication. Graph drawn from data from Ref. [110].
Generic and branded products, used on- and off-label, and whether they are likely targets for clinical data transparency (a) accessibility of data and (b) volume of prescriptions. The areas of the rectangle relate to numbers of prescriptions, normalised to 100%.